History

Sermorelin is the shortest fragment of the 44-amino-acid GHRH that still fully stimulates growth-hormone release from the pituitary. It was developed and marketed by Serono and received FDA approval in 1997 as Geref, for assessing pituitary function and treating growth failure in children. The manufacturer discontinued it in 2008 for commercial reasons, removing the only FDA-approved version from the market; the molecule persists in compounding and research-supply channels.

Sermorelin is one of the oldest peptides in the “growth hormone” category, and unlike most of its peers it once held FDA approval. That history is often used to imply more about its benefits than the evidence supports.

What it is

Sermorelin is a synthetic peptide made of 29 amino acids — the first 29 of human growth hormone-releasing hormone (GHRH), the part that carries the activity. It binds the GHRH receptor on the pituitary and prompts the gland to release its own growth hormone (GH). Because it works upstream and the body’s normal somatostatin brake still applies, GH comes out in pulses rather than as a flat dose. It is injected subcutaneously and clears quickly, with a half-life of roughly 11 to 12 minutes.

The claims

Clinics market sermorelin for anti-aging, more lean muscle and less fat, better sleep, faster recovery, and higher energy — usually framed as a “natural” or “safer” alternative to injected human growth hormone because it stimulates your own production.

What the evidence actually shows

The strongest human data is decades old and narrow. In children with idiopathic growth hormone deficiency, daily sermorelin increased growth velocity in some patients over 12 months, though it generally produced smaller gains than standard somatropin (synthetic GH); it was also used as a diagnostic test of pituitary GH capacity (BioDrugs review, 1999).

In adults, the most-cited trial is small and early: a single-blind, placebo-controlled study of nineteen older men and women (aged 55-71) over about five months found a GHRH(1-29) analogue raised GH and IGF-1 and produced a modest lean-mass change, seen in the men but not the women (Khorram et al., JCEM, 1997). That is a real signal that the mechanism works, but it is a tiny, short study. There are no large, modern randomized controlled trials showing the marketed benefits — fat loss, sleep, recovery, “younger” aging — in healthy adults. Raising a blood marker like IGF-1 is not the same as a proven clinical outcome.

Legal and regulatory status

Sermorelin was FDA-approved under the Geref name — first in 1990 (Geref Diagnostic) for diagnostic evaluation of GH secretion, then in 1997 (Geref) for pediatric growth hormone deficiency. The manufacturer discontinued it around 2008 for commercial reasons and the approvals were subsequently withdrawn; the FDA later confirmed it was not withdrawn for safety or effectiveness problems (Federal Register, 2013). As of 2026 there is no FDA-approved sermorelin product on the market; everything prescribed is made by compounding pharmacies, which is not the same as FDA approval of a finished drug. In sport, sermorelin is banned by WADA at all times as a growth hormone-releasing factor under category S2.

Safety

Short-term tolerability in the older trials and pediatric use was good. The most common side effects were transient facial flushing and injection-site pain or redness. Because it acts through the body’s own regulated GH pathway, sustained overshoot is less likely than with injected GH — but long-term safety in healthy adults using it for anti-aging has not been studied, and theoretical concerns that apply to raising GH/IGF-1 (effects on glucose, fluid retention, and unknown cancer-risk implications) have not been ruled out. Compounded products also vary in purity and dosing. None of this is medical advice.

Bottom line

Sermorelin reliably nudges the pituitary to release growth hormone, and it has genuine, if dated, human data in growth hormone deficiency. But the popular adult anti-aging and body-composition claims rest on small, old, short trials and surrogate markers, not solid modern outcomes. The mechanism is real; the marketing is well ahead of the evidence.

Evidence grade: Preliminary human.